| CAS |
81409-90-7 |
| Chinese Name |
卡麦角林 |
| English Name |
Cabergoline |
| Synonyms |
FCE-21336 |
| Molecular Formula |
C26H37N5O2 |
| Molecular Weight |
451.6 |
| Solubility |
Soluble in DMSO |
| Purity |
≥98% |
| Appearance |
White to off-white Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC |
EINECS 200-419-0 |
| MDL |
MFCD00867887 |
| SMILES |
C=CCN1[C@](C2C[C@@H](C(N(CCCN(C)C)C(NCC)=O)=O)C1)([H])CC3=CNC4=CC=CC2=C43 |
| InChIKey |
KORNTPPJEAJQIU-KJXAQDMKSA-N |
| InChI |
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 |
| PubChem CID |
54746 |
| Target Point |
Dopamine Receptor |
| Passage |
Neuronal Signaling;GPCR & G Protein |
| Background |
It is a long-acting dopamine agonist and prolactin inhibitor. |
| Biological Activity |
Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).[1-2] |
| IC50 |
Ki: 0.7(Dopamine D2 receptor)，1.5(Dopamine D3 receptor)，1.2(5-HT2B receptor)[1] |
| In Vitro |
Cabergoline acts as a potent agonist of D2，D3 and 5-HT2B receptors. Pretreatment with Cabergoline inhibits H2O2-induced neuronal cell death in a dose-dependent manner. In the following experiments，10 μM of Cabergoline is used to investigate its neuroprotective effects. MAP2 staining reveals that Cabergoline significantly suppresses the loss of neurons caused by H2O2 incubation. The detection of apoptotic nuclear condensation suggested that Cabergoline prevents apoptotic cell death following H2O2 exposure[1]. |
| In Vivo |
Cabergoline has a longer elimination half-life(63 to 109 h)compared with other D2-like receptor agonists，both a long-lasting clinical effect following single-dose administration，and an improvement in the quality of life of patients with chronic diseases are expected[1]. The most significant reduction in rapid eye movement(REM)sleep bout number occurred during the light phase，in which Cabergoline-injected female handled mice has 67.3% less REM sleep bouts(F(1，11)=12.892，P=0.004)than Cabergoline-injected females that are restrained，although the greatest number in reduction of REM sleep bouts occurr during the dark phase(82.3% fewer REM sleep bouts; F(1，11)=3.667，P=0.082). In male mice，Cabergoline reduces baseline Prolactin(PRL)levels(98.5%; F(1，6)=13.192，P=0.011)from 5.8±1.3 to 0.08 ng/mL within 2 hours of injection. After a 7-day recovery period，PRL levels return to values that are not different from baseline(5.0±0.60 ng/mL; F(1，6)=0.715，P=0.43)[2]. |
| Cell Experiment |
Primary cortical neurons are prepared. Cabergoline(10 μM; except for experiments of dose-dependency)is applied to cortical cells at DIV 6-7. After 24-hour Cabergoline treatment(except for examination of pretreatment time-dependency of Cabergoline)，H2O2(50 μM; except for the dose-dependency of H2O2)is added. All inhibitors and antagonists，including spiperone，U0126，SB203580，SP600125，AP5，and nifedipine are applied 20 min before Cabergoline or H2O2 addition. L-glutamate is added at DIV 7-8 for cell death induction. Cell survival rate is measured by MTT assay. After the indicated treatment with drugs is completed，culture medium is replaced with 200 μL fresh medium containing 40 μl MTT solution(2.5 mg/mL，diluted in PBS)and cells are incubated at 37°C for 1.5-2.5 hours. Then，200 μL lysis buffer containing isopropyl alcohol is applied to each well and mixed by pipetting. Each sample is moved to a 96-well plate and its absorbance at 570 nm is measured using an iMark Micro plate leader. Cell survival rate is quantitated by absorbance measurement，because MTT(yellow)is deoxidized to formazan(violet)in proportion to mitochondrial activity[1]. |
| Animal Experiment |
Mice[2]Female and male C57BL/6J mice are used.Cabergoline is dissolved in 100% pharmasolve and then diluted with 20% β-cyclodextrin in water to yield a final concentration of 0.15-0.5 mg/mL Cabergoline. Mice received a 0.3-mg/kg ip injection of Cabergoline or vehicle. All drugs are prepared within 48 hours of experiment and stored at 4°C. Solutions are allowed to reach at room temperature before injection. |
| Data Literature Source |
[1]. Odaka H，et al. Cabergoline，dopamine D2 receptor agonist，prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014 Jun 10;9(6):e99271.
[2]. Jefferson F，et al. A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice. Endocrinology. 2014 Nov;155(11):4411-21 |
| Unit |
Bottle |
| Specification |
5mg 10mM*1mL in DMSO 10mg |
English
中文
Manual Download
